MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-07-2026
Aptorum Group Limited Accounts Payables 2011-2026 | APM
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Aptorum Group Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 3.24 M | 2.59 M | 1.25 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.24 M | 1.25 M | 2.36 M |
Quarterly Accounts Payables Aptorum Group Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 4.17 M | - | 3.54 M | - | 3.24 M | - | 2.5 M | - | 2.59 M | - | - | - | 1.25 M | - | - | - | 653 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.17 M | 653 K | 2.56 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Annovis Bio
ANVS
|
1.29 M | $ 2.52 | 1.2 % | $ 22.7 M |  USA |
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | USA |
 |
Actinium Pharmaceuticals
ATNM
|
897 K | $ 1.21 | 0.74 % | $ 36.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
1.97 M | $ 1.62 | 7.28 % | $ 413 M |  Britain |
 |
Axsome Therapeutics
AXSM
|
65.5 M | $ 162.88 | 0.34 % | $ 8.1 B | USA |
 |
Aytu BioScience
AYTU
|
10.6 M | $ 2.58 | 2.38 % | $ 16.2 M | USA |
 |
I-Mab
IMAB
|
570 M | - | - | $ 866 M |  China |
 |
BridgeBio Pharma
BBIO
|
36.2 M | $ 64.71 | -0.99 % | $ 12.4 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
15.8 M | $ 5.32 | 2.31 % | $ 310 M | Britain |
 |
Atara Biotherapeutics
ATRA
|
4.37 M | $ 7.11 | 37.52 % | $ 53.2 M | USA |
 |
Beam Therapeutics
BEAM
|
10.2 M | $ 26.95 | 1.53 % | $ 2.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
51.7 M | $ 9.66 | -2.62 % | $ 625 M | USA |
 |
Biogen
BIIB
|
432 M | $ 184.68 | -0.1 % | $ 27.1 B | USA |
 |
BioVie
BIVI
|
2.2 M | $ 1.34 | -1.47 % | $ 1.98 M | USA |
 |
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
32.8 M | $ 60.17 | -1.55 % | $ 11.5 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
3.58 B | $ 60.1 | -0.32 % | $ 122 B | USA |
 |
Benitec Biopharma
BNTC
|
201 K | $ 12.76 | 12.52 % | $ 525 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | USA |
 |
BioXcel Therapeutics
BTAI
|
16 M | $ 1.72 | 16.22 % | $ 4.36 M | USA |
 |
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | USA |
 |
BeyondSpring
BYSI
|
295 K | $ 1.45 | - | $ 58.5 M | USA |
 |
Cabaletta Bio
CABA
|
4.55 M | $ 3.18 | 0.42 % | $ 3.71 M | USA |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 3.93 | -13.63 % | $ 8.55 B |  Israel |
 |
Capricor Therapeutics
CAPR
|
183 K | $ 29.47 | 5.61 % | $ 789 M | USA |
 |
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M |  Canada |
 |
Catalyst Biosciences
CBIO
|
355 K | $ 11.83 | -2.03 % | $ 779 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | USA |
 |
C4 Therapeutics
CCCC
|
858 K | $ 3.62 | 18.91 % | $ 300 M | USA |
 |
Codexis
CDXS
|
2.84 M | $ 1.23 | -0.41 % | $ 90.3 M | USA |
 |
Cerus Corporation
CERS
|
28 M | $ 1.86 | -3.89 % | $ 355 M | USA |